Vemurafenib is a BRAF inhibitor that is typically used to treat metastatic melanoma; however, this molecular mechanism can trigger RAS mutations due to a paradoxical activation of mitogen-activated protein kinase (MAPK), which can lead to the development of cSCC [19–21]. The gene discussed is WNK2; the disease is metastatic melanoma.